Swiss National Bank Has $30.09 Million Stake in UiPath Inc. (NYSE:PATH)

Swiss National Bank raised its position in UiPath Inc. (NYSE:PATH) by 4.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,211,500 shares of the healthcare company’s stock after acquiring an additional 56,600 shares during the quarter. Swiss National Bank owned approximately 0.21% of UiPath worth $30,094,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Raymond James & Associates increased its holdings in shares of UiPath by 51.0% in the third quarter. Raymond James & Associates now owns 89,534 shares of the healthcare company’s stock valued at $1,532,000 after purchasing an additional 30,244 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of UiPath by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 2,385,317 shares of the healthcare company’s stock valued at $40,813,000 after acquiring an additional 15,334 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in UiPath by 27.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 94,499 shares of the healthcare company’s stock worth $1,617,000 after acquiring an additional 20,491 shares during the period. Mackenzie Financial Corp acquired a new stake in UiPath in the 3rd quarter worth about $2,359,000. Finally, Strs Ohio bought a new stake in UiPath in the 3rd quarter valued at about $786,000. Institutional investors own 62.50% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $19.79, for a total value of $791,600.00. Following the transaction, the chief financial officer now owns 946,848 shares of the company’s stock, valued at $18,738,121.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold 96,000 shares of company stock worth $2,023,440 in the last three months. 31.03% of the stock is currently owned by corporate insiders.

UiPath Trading Down 0.6 %

Shares of PATH stock opened at $19.89 on Thursday. The stock has a market capitalization of $11.32 billion, a P/E ratio of -117.00 and a beta of 1.01. UiPath Inc. has a 12 month low of $13.30 and a 12 month high of $27.87. The firm’s 50 day moving average is $21.60 and its 200 day moving average is $21.78.

UiPath (NYSE:PATH) last announced its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The firm had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. On average, equities analysts predict that UiPath Inc. will post -0.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Barclays lifted their price target on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a research report on Friday, March 15th. Royal Bank of Canada restated a “sector perform” rating and issued a $29.00 target price on shares of UiPath in a report on Monday, April 1st. Evercore ISI raised their target price on UiPath from $24.00 to $27.00 and gave the company an “in-line” rating in a report on Thursday, March 14th. Canaccord Genuity Group upped their price target on UiPath from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Finally, Scotiabank raised their price objective on UiPath from $29.00 to $30.00 and gave the company a “sector perform” rating in a research note on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $27.41.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.